Financials Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 14/02/2025 GMT 5-day change 1st Jan Change
40.67 USD -1.57% Intraday chart for Revolution Medicines, Inc. -3.60% -7.02%

Projected Income Statement: Revolution Medicines, Inc.

Forecast Balance Sheet: Revolution Medicines, Inc.

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 -123 - -577 -645 -1,853 -1,786 -1,149 -717
Change - - - -211.79% -387.29% -196.39% -164.33% -162.4%
Announcement Date 30/03/20 02/03/21 28/02/22 27/02/23 26/02/24 - - -
1USD in Million
Estimates

Cash Flow Forecast: Revolution Medicines, Inc.

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
CAPEX 1 2.589 2.933 6.528 10.82 7.729 11.39 10.88 12.29
Change - 13.29% 122.57% 65.69% -28.54% 47.39% -4.47% 12.95%
Free Cash Flow (FCF) 1 -52.2 -103 -153.7 -235.2 -358.3 -565.5 -657.9 -658.4
Change - 97.29% 49.24% 53.03% 52.33% 57.82% 16.34% 0.09%
Announcement Date 30/03/20 02/03/21 28/02/22 27/02/23 26/02/24 - - -
1USD in Million
Estimates

Forecast Financial Ratios: Revolution Medicines, Inc.

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026

Profitability

        
EBITDA Margin (%) - -251.46% -629.21% -715.77% -4,154.36% -190,894.89% -55,680.36% -18,437.95%
EBIT Margin (%) -108.15% -257.54% -639.7% -730.01% -4,207.12% -191,706.1% -55,389.9% -18,480.64%
EBT Margin (%) -103.99% -252.5% -636.58% -704.14% -3,798.71% -166,792.17% -51,568.52% -17,701.73%
Net margin (%) -123.7% -256.8% -636.58% -702.95% -3,768.28% -167,908.68% -51,347.27% -17,799.77%
FCF margin (%) -104.32% -239.62% -522.99% -664.83% -3,094.14% -163,361.26% -47,513.04% -14,998.55%
FCF / Net Income (%) 84.33% 93.31% 82.16% 94.58% 82.11% 97.29% 92.53% 84.26%

Profitability

        
ROA -31.65% -28.02% -28.66% -32.11% -30.38% -25.2% -33.3% -51.5%
ROE - -68.54% -34.74% -38.63% -34.76% -29.57% -39.29% -63.12%

Financial Health

        
Leverage (Debt/EBITDA) - - - - - - - -
Debt / Free cash flow - - - - - - - -

Capital Intensity

        
CAPEX / Current Assets (%) 5.17% 6.82% 22.21% 30.57% 66.74% 3,290.93% 785.95% 279.98%
CAPEX / EBITDA (%) - -2.71% -3.53% -4.27% -1.61% -1.72% -1.41% -1.52%
CAPEX / FCF (%) -4.96% -2.85% -4.25% -4.6% -2.16% -2.01% -1.65% -1.87%

Items per share

        
Cash flow per share 1 - - - - -3.098 -3.468 -3.623 -
Change - - - - - 11.95% 4.44% -
Dividend per Share 1 - - - - - - - -
Change - - - - - - - -
Book Value Per Share 1 -2.586 8.65 8.127 7.578 16.14 12.27 8.149 5.35
Change - -434.51% -6.05% -6.75% 112.97% -23.96% -33.6% -34.35%
EPS 1 -1.049 -2.01 -2.57 -3.08 -3.86 -3.479 -4.016 -4.253
Change - 91.61% 27.86% 19.84% 25.32% -9.87% 15.43% 5.91%
Nbr of stocks (in thousands) - 66,380 73,687 88,791 164,565 184,795 184,795 184,795
Announcement Date 30/03/20 02/03/21 28/02/22 27/02/23 26/02/24 - - -
1USD
Estimates
2024 *2025 *
P/E ratio -11.7x -10.1x
PBR 3.31x 4.99x
EV / Sales 16,552x 4,598x
Yield - -
More valuation ratios * Estimated data

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Trading Rating
Investor Rating
ESG MSCI
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
40.67USD
Average target price
73.29USD
Spread / Average Target
+80.20%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. RVMD Stock
  4. Financials Revolution Medicines, Inc.